Pre-market Hot Trades in US Stocks
Silexion Therapeutics is down 15.80% in pre-market trading. Based on recent news,
<ol>
<li>
On May 14, Silexion Therapeutics reported positive preliminary immunotherapy results for SIL204 in KRAS-driven pancreatic cancer. This news was initially seen as positive, but the market remains skeptical about its long-term prospects, leading to a decline in stock price.
</li>
<li>
On May 15, Silexion Therapeutics issued a statement mentioning future capital needs and uncertainties, including the ability to maintain its NASDAQ listing. This raised investor concerns and further pressured the stock price.
</li>
<li>
On May 13, the company announced a dual-route dosing strategy in combination with standard chemotherapy, attempting to stand out in the competitive oncology field. However, the market remains cautious about the actual effectiveness of its technology, resulting in stock price pressure. The market maintains a cautious outlook on biotech stocks.
</li>
</ol>
FuelCell Energy is down 7.82% in pre-market trading. There has been no significant news recently; trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news
Top Gainers in Pre-market US Stocks
HCW Biologics is up 205.64% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 14, HCW Biologics released its financial report for Q1 2026, showing progress in the field of innovative combination immunotherapy. Following the release of the report, market confidence in its future growth potential increased, driving a significant rise in stock price.
</li>
<li>
On May 14, HCW Biologics announced that its research found HCW11-040 could prevent bronchopulmonary dysplasia (BPD) in IND-enabled studies. This finding boosted market confidence in the company's R&amp;D capabilities, further stimulating the stock price increase.
</li>
<li>
On May 15, analysts rated HCW Biologics as &#34;Buy,&#34; predicting a 12-month target price of $2.00, which is 472.4% higher than the closing price of $0.35 on May 13. This optimistic analyst expectation provided strong support for the stock price. The biotech industry has been active recently, with significant capital inflows.
</li>
</ol>
Dreamland is up 102.40% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 12, Dreamland signed a memorandum of understanding with LinkFung Innovation to develop an AI-driven smart image library platform. This move is seen as a significant step in strategically expanding the company's market influence, driving the stock price up.
</li>
<li>
On May 13, Dreamland's stock price surged 126.92%, with a trading volume of approximately $219 million, indicating an extremely rare scale of capital inflow. Technical indicators show bullish signals, but further dimensions need to be considered, with market sentiment clearly driving the movement
On May 14, technical analysis showed that Dreamland's stock price far exceeded key moving averages, with an RSI of 97.75, indicating that the stock is extremely overbought and at risk of a sharp correction. There have been no significant positive developments in the movie entertainment industry recently.
</li>
</ol>
Auddia rose 79.52% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 15, Auddia submitted an S-4 filing to merge with Thramann Holdings, establishing McCarthy Finney as a unified AI platform. This move is seen as an important step in the company's strategic expansion, driving a significant increase in stock price. Source: Reuters
</li>
<li>
On May 12, Auddia and the directors and executives of Thramann Holdings participated in a proxy solicitation, with information related to the merger transaction published on the company's website, increasing market confidence in the success of the merger. Source: Auddia Inc.
</li>
<li>
On May 12, Auddia detailed the interests of its directors and executives in its annual report, further enhancing investor trust in corporate governance and supporting the rise in stock price. Source: Auddia Inc. The U.S. stock market has recently experienced increased volatility, and risks should be monitored
</li>
</ol>

SLXN

FCEL

Silexion Therapeutics pre-market down 15.80%; FuelCell Energy pre-market down 7.82%; HCW Biologics pre-market up 205.64%; Dreamland pre-market up 102.40%; Auddia pre-market up 79.52%

Price Alert

Silexion Therapeutics

Pre-market hot trades in US stocks: Silexion Therapeutics pre-market down 15.80%; FuelCell Energy pre-market down 7.82%